Preview

Neurology, Neuropsychiatry, Psychosomatics

Advanced search

The efficacy of ipidacrine in patients with diabetic polyneuropathy

https://doi.org/10.14412/2074-2711-2022-3-38-43

Full Text:

Abstract

Peripheral nervous system involvement in patients with type 2 diabetes mellitus is a severe complication associated with a decrease in the quality of life, the development of disability and lethal outcomes. The most negative in terms of prognosis is autonomic diabetic polyneuropathy (DPN).

Objective: to study the effectiveness of the drug ipidacrine (Ipigrix) in patients with DPN.

Patients and methods. 49 patients with DPN were observed, they were divided into three groups. Patients of the 1st group (n=16) received ipidacrine 20 mg orally 3 times a day for 60 days, patients of the 2nd group (n=17) received ipidacrine 15 mg 1 time per day intramuscularly for 15 days, then – 20 mg 3 times a day orally up to 2 months; patients of the 3rd group (n=16) received only basic therapy. The clinical condition, severity of pain syndrome according to the Neurological Symptoms Score (NSS), vegetative tests, and treatment tolerance were assessed.

Results and discussion. The therapy was effective in terms of reducing the severity of neuropathic pain syndrome, as well as normalizing the results of vegetative tests. In patients of the 1st group, the total scores on the NSS scale decreased by 37% (p<0.05) by the 60th day of treatment. In patients of the 2nd group, the total scores on the NSS scale decreased by 22% by the 30th day (p<0.05) and by 35% (p<0.05) by the 60th day of treatment. A pronounced positive effect in terms of vegetative tests was noted on the 60th day of treatment in the 1st and 2nd groups of patients. No adverse events were observed during the treatment period in any of patients of the 1st and the 2nd groups. In the comparison group, there were no significant changes in scores on the NSS scale and indicators of vegetative samples.

Conclusion. The effectiveness of the drug ipidacrine (Ipigrix) in patients with pain and vegetative manifestations of DPN was noted.

About the Authors

P. R. Kamchatnov
N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia
Russian Federation

1, Ostrovityanova St., Moscow 117997



E. R. Barantsevich
Acad. I.P. Pavlov First Saint Petersburg State Medical University, Ministry of Health of Russia
Russian Federation

6-8, Lva Tolstogo St., Saint Petersburg 197022



A. V. Chugunov
N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia
Russian Federation

1, Ostrovityanova St., Moscow 117997



A. A. Kabanov
N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia
Russian Federation

1, Ostrovityanova St., Moscow 117997



B. A. Abusueva
Dagestan State Medical University, Ministry of Health of Russia
Russian Federation

1, Lenin Sq., Makhachkala



References

1. Dwyer-Lindgren L, Mackenbach JP, van Lenthe FJ, et al. Diagnosed and Undiagnosed Diabetes Prevalence by County in the U.S., 1999–2012. Diabetes Care. 2016 Sep;39(9):1556-62. doi: 10.2337/dc16-0678

2. Beagley J, Guariguata L, Weil C, Motala AA. Global estimates of undiagnosed diabetes in adults. Diabetes Res Clin Pract. 2014 Feb;103(2):150-60. doi: 10.1016/j.diabres. 2013.11.001. Epub 2013 Dec 1.

3. International Diabetes Federation. IDF Diabetes Atlas. 8th ed. Brussels, Belgium: International Diabetes Federation; 2017.

4. Jaiswal M, Divers J, Dabelea D, et al. Prevalence of and Risk Factors for Diabetic Peripheral Neuropathy in Youth With Type 1 and Type 2 Diabetes: SEARCH for Diabetes in Youth Study. Diabetes Care. 2017 Sep;40(9):1226-32. doi: 10.2337/dc17-0179. Epub 2017 Jul 3.

5. Albers J, Herman W, Pop-Busui R, et al. Subclinical neuropathy among Diabetes Control and Complications Trial participants without diagnosable neuropathy at trial completion: possible predictors of incident neuropathy? Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Intervention and Complications (EDIC) Research Group. Diabetes Care. 2007 Oct;30(10):2613-8. doi: 10.2337/dc07-0850. Epub 2007 Jul 20.

6. Boulton A, Vinik A, Arezzo J, et al. American Diabetes Association Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care. 2005 Apr;28(4):956-62. doi: 10.2337/diacare.28.4.956

7. Deli G, Bosnyak E, Pusch G, et al. Diabetic Neuropathies: Diagnosis and Management. Neuroendocrinology. 2013;98(4):267-80. doi: 10.1159/000358728. Epub 2014 Jan 22.

8. Lavery L, Davis K, Berriman S, et al. WHS guidelines update: Diabetic foot ulcer treatment guidelines. Wound Repair Regen. 2016 Jan-Feb;24(1):112-26. doi: 10.1111/wrr.12391

9. Spallone V, Ziegler D, Freeman R, et al. Cardiovascular autonomic neuropathy in diabetes: clinical impact, assessment, diagnosis, and management. Toronto Consensus Panel on Diabetic Neuropathy. Diabetes Metab Res Rev. 2011 Oct;27(7):639-53. doi: 10.1002/dmrr.1239

10. Vinik A, Erbas T. Diabetic autonomic neuropathy. Handb Clin Neurol. 2013;117:279-94. doi: 10.1016/B978-0-444-53491-0.00022-5

11. Freeman R. Diabetic autonomic neuropathy. Handb Clin Neurol. 2014;126:63-79. doi: 10.1016/B978-0-444-53480-4.00006-0

12. Balcioglu AS, Müderrisoglu H. Diabetes and cardiac autonomic neuropathy: Clinical manifestations, cardiovascular consequences, diagnosis and treatment. World J Diabetes. 2015 Feb 15;6(1):80-91. doi: 10.4239/wjd.v6.i1.80

13. Pop-Busui R. Cardiac autonomic neuropathy in diabetes: a clinical perspective. Diabetes Care. 2010 Feb;33(2):434-41. doi: 10.2337/dc09-1294

14. Agashe S, Petak S. Cardiac Autonomic Neuropathy in Diabetes Mellitus. Methodist Debakey Cardiovasc J. 2018 Oct-Dec;14(4):251-6. doi: 10.14797/mdcj-14-4-251

15. Lin K, Wei L, Huang Z, Zeng Q. Combination of Ewing test, heart rate variability, and heart rate turbulence analysis for early diagnosis of diabetic cardiac autonomic neuropathy. Medicine (Baltimore). 2017 Nov;96(45):e8296. doi: 10.1097/MD.0000000000008296

16. Bokeria LA, Bokeria OL, Volkovskaya IV. Heart rate variability: measurement methods, interpretation, clinical use. Annaly aritmologii = Annals of Arrhythmology. 2009;(4):21-7 (In Russ.).

17. Fukuda K, Kanazawa H, Aizawa Y, et al. Cardiac Innervation and Sudden Cardiac Death. Circ Res. 2015 Jun 5;116(12):2005-19. doi: 10.1161/CIRCRESAHA.116.304679

18. Kamchatnov PR, Chugunov AV, Pyshkina LI. The use of alpha-lipoic acid in patients with diabetic polyneuropathy. Effektivnaya farmakoterapiya = Effective Pharmacotherapy. 2019;15(39):23-9. doi: 10.33978/2307-3586-2019-15-39-23-29 (In Russ.).

19. Golovacheva VA, Parfenov VA. Diabetic polyneuropathy: optimal pharmacotherapy and an interdisciplinary approach. Effektivnaya farmakoterapiya. Endokrinologiya. Spetsvypusk “Sakharnyy diabet” = Effective Pharmacotherapy. Endocrinology. Special issue “Diabetes mellitus”. 2017;(9):14-21 (In Russ.).

20. Strokov IA, Fokina AS, Strokov KI, Drokonova OO. Modern principles of diagnosis and treatment of diabetic polyneuropathy. Meditsinskiy sovet = Medical Council. 2014;(5):38-43 (In Russ.).

21. Avakyan GN, Avakyan GG. A clinical-electroneuromyographic study of the efficacy of ipidacrine in patients with mononeuropathies. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2015;115(9):17-22. doi: 10.17116/jnevro20151159117-22 (In Russ.).

22. Katunina EA, Avanesova OV, Pestovskaya OR. The use of acetylcholinesterase inhibitors in the treatment of diseases of the peripheral nervous system. Farmateka = Pharmacea. 2009;15:52-6 (In Russ.).

23. Ziegler D, Gries FA. Alpha-lipoic acid in the treatment of diabetic peripheral and cardiac autonomic neuropathy. Diabetes. 1997 Sep;46 Suppl 2:S62-6. doi: 10.2337/diab.46.2.s62

24. Parfenov VA, Golovacheva VA. Interdisciplinary management of patients with diabetic neuropathy. Effektivnaya farmakologiya. Nevrologiya = Effective Pharmacology. Neurology. 2017;5(38):42-9 (In Russ.).

25. Lunina EYu, Petrukhin IS. Diagnostic value of spectral analysis of heart rate variability for the detection of cardiac autonomic neuropathy in type 2 diabetes mellitus. Rossiyskiy kardiologicheskiy zhurnal = Russian Journal of Cardiology. 2012;3(95):42-6 (In Russ.).


Review

For citations:


Kamchatnov P.R., Barantsevich E.R., Chugunov A.V., Kabanov A.A., Abusueva B.A. The efficacy of ipidacrine in patients with diabetic polyneuropathy. Neurology, Neuropsychiatry, Psychosomatics. 2022;14(3):38-43. (In Russ.) https://doi.org/10.14412/2074-2711-2022-3-38-43

Views: 60


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2074-2711 (Print)
ISSN 2310-1342 (Online)